{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:43:33Z","timestamp":1792215813919,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clinre.2026.102898","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:48:19Z","timestamp":1785944899000},"page":"102898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of empagliflozin in metabolic dysfunction\u2013associated steatotic liver disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"50","author":[{"given":"Shambo Samrat","family":"Samajdar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank R","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurab","family":"Bhaduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banshi","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnendu","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9524-1525","authenticated-orcid":false,"given":"Shatavisa","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehal","family":"Bansode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clinre.2026.102898_bib0001","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70132","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): mechanisms, clinical implications and therapeutic advances","volume":"8","author":"Miller","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"issue":"2","key":"10.1016\/j.clinre.2026.102898_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101898","article-title":"Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045","volume":"30","author":"Kan","year":"2025","journal-title":"Ann Hepatol"},{"issue":"10","key":"10.1016\/j.clinre.2026.102898_bib0003","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.4254\/wjh.v13.i10.1203","article-title":"Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease","volume":"13","author":"Alam","year":"2021","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102898_bib0004","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12933-025-02824-3","article-title":"Fatty liverresearch group of the Korean diabetes association. Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality","volume":"24","author":"Han","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102898_bib0005","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jceh.2021.06.015","article-title":"Saroglitazar for nonalcoholic fatty liver disease: a single centre experience in 91 patients","volume":"12","author":"Padole","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.clinre.2026.102898_bib0006","unstructured":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. Accessed from https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease#:~:text=In%20this%20section-,Press%20Announcements,along%20with%20diet%20and%20exercise."},{"issue":"11","key":"10.1016\/j.clinre.2026.102898_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70407","article-title":"Focus on Semaglutide 2.4\u2009mg\/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis","volume":"45","author":"Petta","year":"2025","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.clinre.2026.102898_bib0008","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s40279-023-01918-w","article-title":"Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: a position statement from exercise and sport science Australia","volume":"53","author":"Keating","year":"2023","journal-title":"Sports Med"},{"issue":"7","key":"10.1016\/j.clinre.2026.102898_bib0009","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3390\/pharmaceutics15071963","article-title":"Pharmaceutical strategies to improve druggability of potential drug candidates in nonalcoholic fatty liver disease therapy","volume":"15","author":"Amatya","year":"2023","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.clinre.2026.102898_bib0010","article-title":"Empagliflozin and cardiovascular outcomes: a systematic review of randomized controlled trials in populations with diabetes and heart failure","volume":"17","author":"Ansar","year":"2025","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.clinre.2026.102898_bib0011","doi-asserted-by":"crossref","first-page":"964","DOI":"10.4093\/dmj.2025.0644","article-title":"Hepatic insulin resistance and steatosis in metabolic dysfunction-associated steatotic liver disease: new insights into mechanisms and clinical implications","volume":"49","author":"Truong","year":"2025","journal-title":"Diabetes Metab J"},{"issue":"2","key":"10.1016\/j.clinre.2026.102898_bib0012","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet Fed ApoE(-\/-) mice by activating autophagy and reducing er stress and apoptosis","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinre.2026.102898_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.622153","article-title":"Empagliflozin alleviates hepatic steatosis by activating the AMPK-TET2-autophagy pathway in vivo and in vitro","volume":"11","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102898_bib0014","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.clinre.2026.102898_bib0015","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled Trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.clinre.2026.102898_bib0016","first-page":"298","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4","volume":"43","author":"Kahl","year":"2020","journal-title":"Placebo-Controlled Trial Diabetes Care"},{"issue":"3","key":"10.1016\/j.clinre.2026.102898_bib0017","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.clinre.2026.102898_bib0018","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102898_bib0019","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","article-title":"Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Cheung","year":"2024","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2026.102898_bib0020","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2337\/dc23-1646","article-title":"Empagliflozin reduces liver fat in individuals with and without diabetes","volume":"47","author":"Abdelgani","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinre.2026.102898_bib0021","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12902-025-01882-8","article-title":"The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"25","author":"Shojaei","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.clinre.2026.102898_bib0022","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinre.2026.102898_bib0023","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.clinre.2026.102898_bib0024","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence\u2013study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102898_bib0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12902-025-02098-6","article-title":"Effect of empagliflozin on liver fibrosis and steatosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized clinical trial","volume":"25","author":"Erfanifar","year":"2025","journal-title":"BMC Endocr Disord"},{"issue":"10","key":"10.1016\/j.clinre.2026.102898_bib0026","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.3390\/biomedicines13102437","article-title":"Endoscopic bariatric therapies for metabolic dysfunction-associated steatotic liver disease: mechanistic insights and metabolic implications","volume":"13","author":"Ghusn","year":"2025","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.clinre.2026.102898_bib0027","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v17.i8.109796","article-title":"Assessment of liver stiffness measurement-related markers in predicting liver-related events in viral cirrhosis with clinically significant portal hypertension","volume":"17","author":"Li","year":"2025","journal-title":"World J Hepatol"},{"issue":"12","key":"10.1016\/j.clinre.2026.102898_bib0028","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.12998\/wjcc.v10.i12.3662","article-title":"Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis","volume":"10","author":"Garbuzenko","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.clinre.2026.102898_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155657","article-title":"SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis","volume":"146","author":"Shen","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.clinre.2026.102898_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/srep16163","article-title":"MiR-146a-5p suppresses activation and proliferation of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis through directly targeting Wnt1 and Wnt5a","volume":"5","author":"Du","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clinre.2026.102898_bib0031","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102898_bib0032","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinre.2026.102898_bib0033","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2147\/DMSO.S185705","article-title":"Progressive reduction in skeletal muscle mass to visceral fat area ratio is associated with a worsening of the hepatic conditions of non-alcoholic fatty liver disease","volume":"12","author":"Shida","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"7","key":"10.1016\/j.clinre.2026.102898_bib0034","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164296","article-title":"Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition","volume":"8","author":"Kogot-Levin","year":"2023","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.clinre.2026.102898_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000871","article-title":"Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism","volume":"8","author":"Green","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.clinre.2026.102898_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol Metab"},{"issue":"5","key":"10.1016\/j.clinre.2026.102898_bib0037","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease","volume":"36","author":"Bo","year":"2024","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.clinre.2026.102898_bib0038","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.clinre.2026.102898_bib0039","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14348\/molcells.2021.2147","article-title":"Increased hepatic lipogenesis elevates liver cholesterol content","volume":"44","author":"Berger","year":"2021","journal-title":"Mol Cells"},{"key":"10.1016\/j.clinre.2026.102898_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1669613","article-title":"Comparative effectiveness of empagliflozin versus dapagliflozin in adults with metabolic dysfunction-associated steatotic liver disease","volume":"16","author":"Wu","year":"2025","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clinre.2026.102898_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.clinre.2026.102898_bib0042","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-025-02084-x","article-title":"Empagliflozin and its impact on hepatic and metabolic outcomes in patients with type 2 diabetes and NAFLD: a systematic review and meta-analysis","volume":"18,","author":"Hamzah","year":"2026","journal-title":"Diabetol Metab Syndr"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:17:46Z","timestamp":1792214266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126001440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2210740126001440"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102898","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of empagliflozin in metabolic dysfunction\u2013associated steatotic liver disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102898"}}